The pandemic has put life into perspective for ResMed boss Mick Farrell. The chief executive of the dual-listed $US28 billion ($35.9 billion) sleep disorder and digital health giant spent four weeks with his family in Greece and Tanzania in mid-2019 on a rare break – and a tick off his bucket list.
But by early January 2020, there was word from China that Wuhan hospital customers were ramping up ventilator orders from ResMed’s Suzhou factory. Not long after, San Diego-based Farrell found himself locked down for what became the best part of a year as COVID-19 tightened its grip.